Thông tin cho nhân viên y tế
Thuốc mới và thông tin từ Drugs.com
- Basel, October 7, 2026 – Novartis announced today that the U.S. Food and Drug Administration (FDA) approved Rhapsido® (remibrutinib), an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), as the first treatment for…
- NEW YORK–(BUSINESS WIRE) October 7, 2026 — Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Tukysa (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of…
- INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a…
- PRINCETON, N.J.–(BUSINESS WIRE) September 30, 2026 — Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos (mavacamten) for the treatment of symptomatic obstructive hypertrophic…
- STOCKHOLM, SWEDEN, Sept. 28 2026. (GLOBE NEWSWIRE) – Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX) today announced that the U.S. Food and Drug Administration (FDA) has approved Emcitate (tiratricol), a…
- TEL AVIV, Israel, and PARSIPPANY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved Degevma (denosumab-adet) as a…
- WEDNESDAY, Oct. 7, 2026 — Youth who ride electric- or gas-powered bikes have a higher risk for trauma or death when involved in collisions compared with those riding pedal bicycles, according to a study presented at the annual American Academy of…
- WEDNESDAY, Oct. 7, 2026 — For patients with treatment-resistant major depressive disorder (trMDD), stereotactic radiosurgical (SRS) capsulotomy shows promise, according to a study presented at the annual meeting of the American Society for…
- WEDNESDAY, Oct. 7, 2026 — Statin use is associated with a lower risk for glaucoma incidence and treatment escalation, according to a study published online Oct. 6 in the British Journal of Ophthalmology. Forest Lin, from the Morsani College of…
- WEDNESDAY, Oct. 7, 2026 — Radiation therapy (RT) and radical prostatectomy (RP) have distinct morbidity profiles that support individualized treatment decisions, according to a study presented at the annual meeting of the American College of…
- WEDNESDAY, Oct. 7, 2026 — Certain pregnancy complications are associated with an increased risk for cardiometabolic-renal conditions in subsequent years, according to a study published online Oct. 6 in BMJ Medicine. Steven Wambua, Ph.D., from the…
- WEDNESDAY, Oct. 7, 2026 — Nail disorders and hair and scalp changes occur frequently among glucagon-like peptide-1 receptor agonist (GLP-1 RA) users, according to two studies presented at the annual meeting of the European Academy of Dermatology…
Thông tin từ The Pharma Letter
- The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved catumaxomab (trade name Korjuny) to treat malignant ascites in adults when standard treatment of their cancer is no longer feasible.
- US drug delivery company Halozyme Therapeutics has said that the specialized Dutch patent court in The Hague has found Merck & Co to be infringing one of its MDASE patents, EP 2,797,622, and has granted an injunction against sales of subcutaneous Keytruda (pembrolizumab) in several European countries.
- UK-based Pharmanovia has appointed Béchir Ben Hadj Yahia as global head of medical affairs, as it expands its presence in specialty oncology.
- US biotech Matchpoint Therapeutics today announced the successful closing of a $150 million Series B financing.
- Indian pharma major Lupin has launched Formoflo-G MDI, a fixed-dose triple-combination metered-dose inhaler (MDI) for moderate to severe chronic obstructive pulmonary disease (COPD), following approval from the Drug Controller General of India.
- San Diego, USA-based Halozyme Therapeutics announced that it has expanded its global collaboration and license agreement with Dutch immunology company argenx to develop and commercialize ENHANZE with two additional exclusive targets.
Thông tin từ BioPharmaDive
- Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure funding to support the effort and will now pursue “strategic alternatives” instead.
- A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.
- Cerevance plans to meet with the FDA to determine next steps for a new kind of medicine known as solengepras, now that it has Phase 3 data in hand.
- The fundraise is the firm’s largest to date, providing a lift for a European biotech industry that’s fallen further behind its counterparts in the U.S. and China.
- More than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share.
- The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.
Thông tin từ STAT News
- About half of the patients in a study regained photosensitivity in their vision, showing the promise of optogenetics.
- The Trump administration has proposed a $70,000 fee for a popular work authorization program meant to give students professional experience
- The brand drug industry’s main trade group is suing the Trump administration over a pilot program tying Medicare drug prices to those in peer countries.
- In a setback for Merck, a Dutch court ordered a halt to the manufacturing and marketing of a subcutaneous formulation of Keytruda in several European countries.
- Forbion, a prominent European venture capital firm, said it has raised $2.6 billion, its largest fundraise to date and one of the largest in the region in recent years.
- In this edition of STAT's AIP Prognosis: Unresolved regulatory questions around Utah's AI sandbox, and more health AI news.
Thông tin từ Nature Review Drug Discovery
- Nature Reviews Drug Discovery, Published online: 07 October 2026; doi:10.1038/s41573-026-01534-zImmune cell engagers are emerging as a strategy for deep B cell depletion in autoimmune diseases. This Review examines their mechanisms, clinical development and next-generation designs, including T cell, natural killer cell and γδ T cell-engaging formats, and considers lessons from haematological malignancies to improve efficacy, […]
- Nature Reviews Drug Discovery, Published online: 07 October 2026; doi:10.1038/d41573-026-00163-wMolecular glue targets ALK resistance
- Nature Reviews Drug Discovery, Published online: 05 October 2026; doi:10.1038/d41573-026-00162-xAstraZeneca’s tozorakimab reduced disease flare ups in patients with COPD, suggesting IL-33-targeted antibodies could offer broad potential in pulmonary diseases.
- Nature Reviews Drug Discovery, Published online: 05 October 2026; doi:10.1038/d41573-026-00161-yProbing the many benefits of GLP-1 receptor agonists
- Nature Reviews Drug Discovery, Published online: 05 October 2026; doi:10.1038/d41573-026-00160-zGene therapy for rare lysosomal storage disorder nabs FDA approval
- Nature Reviews Drug Discovery, Published online: 30 September 2026; doi:10.1038/s41573-026-01535-ySoft drugs are designed to enhance drug safety, undergoing rapid and predictable metabolic inactivation after exerting their therapeutic effect. This review provides an overview of the principles of soft drug design, highlighting examples of topical soft drugs in development, practical considerations, ongoing challenges and future directions.